Skip to main content
Premium Trial:

Request an Annual Quote

Scale Biosciences: Giovanna Prout, Jackie Fidanza, John Hu, Scott McCuine

Scale Biosciences, a developer of single-cell sequencing products, recently expanded its executive leadership team, naming Giovanna Prout as CEO, Jackie Fidanza as chief operating officer, John Hu as VP of finance, and Scott McCuine as VP of business development.

Prout was previously VP of marketing at Deepcell. Before that she held marketing and commercial leadership roles of increasing responsibility at 10x Genomics and Illumina. She holds a BS in engineering and an MBA from the University of California, San Diego.

Fidanza joins Scale from Twist Bioscience, where she most recently held the role of VP of operations. Before that she served as VP of manufacturing and senior director of manufacturing at Twist. Fidanza has also served as a leader of R&D/operations at Thermo Fisher Scientific. She holds a BS and PhD in chemistry from Boston College.

Hu previously served as VP of finance for IonPath, director of finance for Coherent, and director of FP&A and treasury at Reliant Technologies. He has also previously served as finance manager in business development and marketing for Roche Molecular Systems. Hu has an MBA from UC, Berkeley, and an MS in chemistry from the University of Miami.

McCuine also joins Scale from Twist Bioscience, where he most recently served as director of business development. Prior to that, he was senior business development manager for next-generation sequencing and senior sales manager, Americas, for NGS at Twist. McCuine has also been a genomics product specialist at Agilent Technologies. He holds an MBA from the Babson F.W. Olin Graduate School of Business and a BS in biochemistry and genetics from Texas A&M University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.